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ABSTRACT
There is a growing need (in the medical field) to design personalized therapy for cancer
patients. Decades of cancer research have found no silver bullet that can cure all or even most
patients. This study evaluated four patients affected by central nervous system (CNS) tumors
(Ependymoma and Glioblastoma), and found that tumors with the same histology had unique
responses to treatment. Each sample presented different levels of heterogeneity in expressed
biomarkers and responded to drugs at varying levels.
Oncologists conventionally treat cancer patients with drugs tested in large clinical trials.
However, often patients do not experience positive outcomes following treatments with standardof-care first line drugs and oncologists need to treat them with a different second-line anticancer
therapy that is chosen empirically. This study was designed to find a way to better predict
patient’s response to chemotherapeutic drugs. The focus of this study was on Central Nervous
System (CNS) tumors because of their limited response to anticancer drugs and their low
survival rate. The uniqueness of this study revealed that each patient’s tumor had different drug
sensitivities and that screening for multiple drugs may increase the chance of finding a drug from
which the patient would have the most benefit.
More importantly this study evaluated the Cancer Stem-Like Cell (CSLC) population
sensitivity to these drugs. This subpopulation is responsible for initiation and maintenance of the
tumor and is known to be resistant to chemotherapy drugs. Dr. Claudio’s laboratory developed a
test capable of determining the cytotoxic drug to which cancer cells and CSLCs of an individual
tumor are most responsive. In the future this procedure may focus the treatment of CNS patients
to drugs effective against their particular tumor allowing them to have better outcomes with
fewer detrimental side effects.
xv

CHAPTER 1: DEVELOPMENT OF A PERSONALIZED
CHEMOTHERAPY ASSAY
INTRODUCTION
The typical treatment for most cancer is surgery followed by chemotherapy and/or
radiation therapy combined in various modalities (1). Ordinarily, the type of chemotherapy or
amount used is based on histology, clinical characteristics of the patient, and retrospective
evidence from randomized clinical trials (2). The standard approach for the treatment of brain
cancer is also surgery followed by chemoradiation therapy. However; the chemotherapy choices
are more limited due to the Blood Brain Barrier (BBB), which may limit diffusion of the drugs
from the blood stream to the nervous tissue (3,4). There are several CNS tumor types and overall
for all types of malignant brain tumors in adults, around four out of ten people diagnosed (40%)
live for at least a year. About 19 out of every 100 people (19%) live for at least five years after
diagnosis, and around 14 out of every 100 people diagnosed (14%) live for at least ten years.
Unfortunately 50% of all CNS cancers diagnosed are Glioblastoma Multiforme (GBM), which
shows the lowest survival rate of all, with survival only being 12-18 month after diagnosis (3).
With such a short survival time, the patient rarely has a second or third round of treatment.
Oncologists cannot predict if a chemotherapeutic agent will be effective for a patient
beforehand, all they can determine is that a particular drug has been effective in a percentage of
patients either from their own experience or from large randomized clinical studies (2). Patients
with the same tumor histotype often respond differently to the same chemotherapy regimen due
to heterogeneity of the tumor (2). Following an initial treatment with drugs used as first-line
chemotherapies, the treating physician will be able to determine if the patient is responding or
not to a particular chemotherapy regimen. Tumor relapse may still occur in spite of an initial
1

response because of the presence of a subset of cells that are resistant to the treatment (5). Toxic
side effects may also decrease patients’ quality of life. Most chemotherapies impact several
important functions and organs of the human body that have cells undergoing a rapid turnover by
having active cellular divisions, such as the hematopoietic compartment, the colon, and the hair
follicles thereby causing immune depression, diarrhea, and hair loss. Additionally,
chemotherapy may also diminish the patients’ memory and learning abilities (6). Therefore, it
would be advantageous to both the patient and the doctor to know whether a chemotherapeutic
agent will be effective against the patient’s tumor cells. This approach would increase efficacy
against the tumor, reduce toxicity and side effects for the patient, prolong response, and reduce
medical cost.
Because of these concerns many different scientists have been looking into therapeutic or
diagnostic approaches to personalize patient therapy. Next Generation Sequencing (NGS) aims at
determining genomic markers that would predict the patient’s sensitivity to a specific
chemotherapeutic agent (7). Evidence linking genetic information to therapeutic effectiveness of
treatments can be misleading. Following the discovered association of KRAS mutations with
resistance to anti‐EGFR antibodies, some studies have shown that tumors with normal ‘wild‐
type’ KRAS profile, still do not respond to therapy (8). This type of research is still in its infancy
and needs more time to progress as research furthers the understanding of tumor biology.
Other researchers have developed a method to determine the sensitivity of cancer cells to
chemotherapeutic agents (total cancer cell population). However, their studies show no accurate
and statistically significant correlation to patients’ disease outcomes (9-12). In the present study
the developed method for personalized chemotherapy uses a biopsy from the patient, which
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allows for testing of the total cancer population and also the CSLCs against standard-of-care
chemotherapy drugs.

CNS Cancer
There are several types of tumors of the central nervous system (CNS); however CNS
tumors are only 1.4% of all new cancers diagnosed in the United States (13) (SEER Stat Fact
Sheets: Brain and Other Nervous System Cancer.
http://seer.cancer.gov/statfacts/html/brain.html). Gliomas are typically found in adult cases and
are fast growing brain tumors typically arising from the supportive tissue of the brain: the “glia”.
Three types of normal cells that constitute the glia can become cancerous. Astrocytes will form
astrocytomas, including glioblastoma. Oligodendrocytes will transform into oligodendrogliomas,
and ependymal cells form ependymomas (13,14). Gliomas are further classified by the World
Health Organization (WHO) according to their grade. Low grade gliomas (WHO grade II) are
well differentiated tumors that tend to have better prognoses. High-grade gliomas (WHO grade
III Astrocytoma, WHO grade III Ependymoma, and WHO grade IV glioblastomas) are
undifferentiated (anaplastic) and carry the worse prognosis. The highly malignant anaplastic
gliomas display hypercellularity, nuclear atypia, and high mitotic activities at histopathologic
examination (13,14). This study focused on high-grade Astrocytomas known as Glioblastoma
Multiforme (GBM) and high-grade Ependymoma.
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Standard-of-Care Drugs
Several factors were taken into account when determining what drugs would be used for
this study. 1. NCCN guide lines, 2. Treating Physician and Pharmacist consultation, 3.
Availability of drug. 4. Mechanism of drugs cytotoxicity. All mechanisms of action for drugs
used were reviewed to ensure cytotoxicity was a measurable endpoint.
Arabinoside-C (Ara-C), also known as Cytosine Arabinoside, interferes with the
synthesis of DNA by rapidly conversion to Cytosine Arabinoside triphosphate, which damages
DNA during DNA synthesis, and also inhibits both DNA and RNA polymerases and nucleotide
reductase enzymes needed for DNA synthesis (15).
Bevacizumab (Avastin) is a monoclonal antibody, its mechanism of action is to block
angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A) (16). The antibody
stops the receptor from being activated and cuts off any new blood supply to the growing tumor,
causing the growth to stop (17). However, this drug has been known to also have cytotoxic
effects but the mechanism is still debated (18). VEGF-targeted therapies, such as bevacizumab,
exert their effects through a number of potential mechanisms, including (1) inhibition of new
vessel growth, (2) regression of newly formed tumor vasculature, (3) alteration of vascular
function and tumor blood flow ("normalization"), and (4) direct effects on tumor cells by
activation of apoptosis (19).
Busulfan (BUS) is an alkylating agent that forms DNA-DNA crosslinks between the
DNA bases guanine and adenine and between guanine and guanine which prevents DNA
replication (20). These DNA crosslinks cannot be repaired, so the cells undergo apoptosis.
Carboplatin (CPL) is a second generation platinum drug (21). Two mechanisms of action
have been proposed: the aquation hypothesis and the activation hypothesis (22). The aquation
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hypothesis proposes that the drug complex aquates and reacts with DNA like cisplatin (22,23).
The difference is in the rate of activity between the faster Carboplatin and Cisplatin (24). The
activation hypothesis assumes that Carboplatin is biologically activated and that it is an unknown
platinum species that binds to the DNA (22). Carboplatin requires a much lower and more
tolerable dose that is then activated within the cell itself (22).
Carmustine (BCNU) is a mustard gas compound used as an alkylating agent in
chemotherapy (25). It disassociates to yield 2-chloroethyl isocyanate and the chloroethyl
carbonium ion intermediate, which is the alkylating moiety (25). As an alkylating agent, BCNU
is able to form interstrand crosslinks in DNA; thereby DNA cannot replicate or be transcribed
(25).
Cisplatin (CDDP) is a platinum drug that causes DNA intrastrand cross-links between
two adjacent guanine residues on the same DNA strand (6,21,23). Patients that have
overexpression of ABCG2 and other multidrug resistance are not responsive to CDDP (6). It is
of note that CDDP causes severe toxicity, which has led to the development of several second
generation platinum drugs (21,26).
Topoisomerase II is a primary cellular target for Etoposide (VP-16) (27). Without
topoisomerase II cells cannot resolve the knots and tangles in the genetic material that are
produced by normal cellular processes (27). Etoposide inhibits topoisomerase II and in its
absence the cells are unable to replicate DNA and the cells die as a consequence of mitotic
failure (27).
Irinotecan (Camptosar, CPT-11) is a topoisomerase-I inhibitor, which is a nuclear
enzyme associated with relaxation of the supercoiled DNA (28,29) that produces reversible
single-strand breaks in DNA during DNA replication. These single-strand breaks relieve

5

torsional strain and allow DNA replication to proceed. Irinotecan binds to the topoisomerase IDNA complex and prevents religation of the DNA strand, resulting in double-strand DNA
breakage and cell death (29).
Lomustine (CCNU) is another DNA alkylating agent (30,31). Lomustine’s full
mechanism of action has not been fully understood but more recent studies have shown that
CCNU triggers apoptosis through the intrinsic apoptosis mitochondrial pathway (31). Its
mechanism of action also involves the inhibition of both DNA and RNA synthesis through DNA
alkylation. Lomustine has been shown to affect a number of cellular processes including: RNA
and protein synthesis; the processing of ribosomal and nucleoplasmic messenger RNA; DNA
base component structure; the rate of DNA synthesis and DNA polymerase activity. It is cell
cycle nonspecific.
Methotrexate (MTX) binds to and competitively inhibits Dihydrofolate Reductase
(DHFR) an enzyme that participates in tetrahydrofolate synthesis (32). Without this reaction the
biosynthesis of purines, thymidylate, and several amino acids is inhibited and the cells cannot
replicate or repair DNA (32).
Oxaliplatin (OXA), like the other platinum drugs causes intrastrand adducts. Oxaliplatin
belongs to the 1,2-diaminocyclohexane (DACH) carrier ligand family whereas cisplatin and
carboplatin belong to cis-diammine. Oxaliplatin is a bulky hydrophobic DACH ligand, which
prevents binding of DNA repair proteins (23). This was the first drug approved that could
overcome cisplatin resistance (23,26).
Procarbazine (PCB) has multiple mechanisms of action (33). It inhibits incorporation of
small DNA precursors, as well as inhibits RNA and protein synthesis (33). PCB can also directly
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damage DNA through an alkylation and methylation reaction (33,34). It is almost always
administered in combination with CCNU and VCR (33,35).
Temodar (TMZ) is commonly used as a first-line drug for high grade gliomas (6). TMZ is
a DNA-alkylating agent and methylating agent (6,35) which delivers a methyl group to purine
bases of DNA (O6-guanine; N7-guanine and N3-adenine). This methylation of guanine residues
leads to single and double-strand DNA breaks and subsequent apoptotic cell death.
Vincristine (VCR) is an alkaloid derived from Vinca rosea Linn (36). It is known to
disrupt mitosis by interfering with microtubules. Like other vinca alkaloids, Vincristine may also
interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent
Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis
(30,37).

Cancer Stem Cell Theory
Dr. John Dick is credited with the discovery of Cancer Stem-Like Cells. The Cancer
Stem-Like Cell theory describes cancer stem-like cells (CSLCs) as a subpopulation that initiates
and maintains cancer, allowing for recurrence and therapy resistance (38-40). However, since
then the Cancer Stem-Like Cell theory has been one of controversy (41). “This controversy
developed because “the definition” of a cancer stem cell needs to be linked to the functional
assay that is used to identify it. Also it needs to be clearly understood that the “cell of origin”
(stem cell or not) represents a different issue” according to Dr. John Dick (42).
The consistent question is whether a cancer always originates from normal stem cells
which lose the control of proliferation and differentiation, or is it a differentiated cell that
becomes more stem-like after acquiring mutations (42-44). Defining CSLCs as a subpopulation
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of tumor cells able to develop their cancer tissue type and regenerate a phenotypically
heterogeneous cell line, like that of the original tumor, implies that CSLCs are the driving force
of cancer recurrence (5). The difficulty to experimentally address this question arises from the
limited quantity of this subpopulation of CSLCs in a given tumor (43). This may one day be
addressed by the ability to isolate and enrich this population (45).
This study evaluates CD133+ subpopulation of CNS tumors for isolation and testing.
CD133 is also known as Prominin-1 (Prom-1), a pentaspan membrane glycoprotein (46). CD133
was first identified as a hematopoietic stem cell marker and since then has been shown to be a
marker of cancer stem-like cells with prominent tumorigenic potential (46). Its function is not
fully understood but is believed that in tumor cells it regulates the proliferation and colonyformation of cancer cells (6, 45-50). CD133 has also been associated with CSLC population in
many tumor types including Glioblastoma, Ependymoma, Medulloblastoma, and Meningioma
(47-49). The role of CD133 as a CSLC marker has been actively investigated over the years (46).
It is accepted that glioma stem-like cells have high expression of CD133 that is similar to neural
stem/progenitor cells (6,46).

Clinical Study
The clinical study using the chemosensitivity assay was set up with the following steps:
1. Receive the biopsy. 2. Disassociate and grow the cells in a monolayer. 3. Determine the
biomarkers that identify CSLCs. 4. Treat bulk cells with various chemotherapeutic agents. 5.
Expand CSLCs and treat them with various chemotherapeutic agents. 6. Analysis of
chemosensitivity data and correlation to clinical outcome.

8

The tumor biopsies from the CNS patients were received in a transfer/collection media
tube. This consisted of RPMI and 10% FBS with 4% Penicillin/Streptomycin. During surgery a
piece of the tumor was collected and placed in this collection tube, which allowed time for any
introduced contamination to be exposed to high levels of antibiotic, reducing the risk of growth
of contaminant bacteria. Culture viability tests were run to show that the tissue remained viable
for several days following collection at room temperature (Figure 1).

9

Figure 1. CNS Tumor collected and processed at different times after collection.
Once biopsy was received tissue was cut into three pieces. Top: Tissue was processed immediately and
incubated for five days. Middle: Tissue was left in test tube with transfer/collection media for three days
at room temperature then processed and incubated for five days. Bottom: Tissue was left in test tube with
transfer/collection media for five days at room temperature then processed and incubated for five days.

Once received by the lab the tissue was washed thoroughly. If the received tissue was
bloody, then it was washed with PBS several times in attempt to reduce the amount of Red Blood
Cells (RBCs) that would be in the culture. After this initial washing, one more wash with 100%
Penicillin/Streptomycin was conducted before manual disassociation technique. To manually
disassociate the tissue a sterile scalpel was used to mince the tissue. The minced tissue was
collected into a 15 mL sterile tube with equal amounts of 0.25% Trypsin and 0.1uM EDTA
10

Accutase. The volume of trypsin and accutase mixture varied based on the amount of tissue
received. The tube was then placed in a 37°C water bath for 5-15 minutes (until the solution
looked cloudy) and then the tissue was transferred into a tissue culture treated dish and normal
culture media was added to stop the digestion (45,50). The primary culture was observed using a
bright field inverted microscope every day for about two weeks and then a regular sub culture
technique began (45,50). Once several tissue culture treated dishes were sub-cultured, several
stocks were made and cryopreserved.
To determine presence of CSLCs in the primary culture obtained, flow cytometry using
fluorescent antibodies against known CSLC markers were used (3,6,38,40,45-55). For flow
cytometry analysis, 1x10 primary cells were collected, stained using specific antibodies and
analyzed using an Accuri C6 Flow Cytometer (45,50). Unspecific isotype antibodies were used
as controls. The isotype control is a base antibody with just the unspecific clone that has a
fluorescent marker added; it detects unspecific binding to remove any false positives from the
test. Expression of every marker tested was calculated by subtracting the value calculated from
sample stained with the isotype antibody. This initial testing is important to verify that the
CSLCs are enriched in the following steps of the test.
The amounts of drugs were based on the clinical dose. The equations used were: Stock
concentration () = (

 

 /. . ) ∗ 1000, In vitro dose() =

(      (/ ) ∗ 1.6)/. . , Amount of stock needed to treat cells
= (

  /

!

 

) ∗ 1000 = ul of stock/ml of media. This concentration

was added to the culturing medium to treat the cells for a one hour pulse to mimic the highest
concentration of chemotherapy drug to which cancer cells would be exposed in a treated patient.

11

Medium was then removed and cells were fed with complete medium containing 10% FBS for
24 hours and assayed using an MTT assay.
Methyl-Thiazolyl-Tetrazolium (MTT) proved to be an accurate assay for determining cell
viability for this chemotherapy sensitivity assay (56). MTT is a yellow powder called (3-(4, 5dimethylthiazole-2-yl)-2, 5-diphenyltetrazoli-umbromide) that is reduced by mitochondrial
dehydrogenase in viable cells, forming a purple formazan precipitant (56). After a 2-4 hour
incubation the media with MTT is removed and the precipitant can then be solubilized using
50ul of DMSO per well. Once the 96 well plate is briefly shaken the plate can be read on a
spectrophotometer at 550nm absorbance. The readings provide the absorbance of the control and
each of the treatments, by taking the (mean of the treatments/means of the controls)*100= %
viable compared to control. This assay is widely used to assess cell viability after imitation of
cytotoxicity (57), however this has been challenged in recent years. One reason that this is
challenged is because MTT can react with compounds used in treatment. This was avoided by
mixing the chemotherapeutic agents used with the MTT and evaluating the absorbance. No
change was found (data not shown). The other challenge with using the MTT assay is that not all
cells have the same amount of mitochondrial activity which is where the MTT is enzymatically
changed into the purple formazan percipient. This is especially a problem with established cell
cultured lines. It was found in primary lines to be less of a challenge because less genetic shifts
have happened. However, a comparison of the MTT assay to several other types of viability
assays (CyQUANT, WST-8, and ATP luciferase) was performed on the primary cultures and
found that there was no statistical difference among the different types of assays tested (Figure
2). In particular, the WST-8 assay was found to be a more reliable alternative if cells were not
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attaching to the surface of the 96-well dishes because WST-8 is water soluble and it doesn’t
require washing steps that are necessary in an MTT assay (58).

Figure 2. MTT vs. CyQUANT vs. WST-8 vs. ATP.
Using a GBM primary cell line to compare MTT assay, CyQUANT, WST-8 and ATP luciferase assay.
Each assay was plated with 1x104 cells per well. All assays were treated with one-hour pulse of
chemotherapeutic agents then analyzed 24 hours later. P-value was greater than 0.5 when comparing the
assays.
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Isolation of CSLCs from the tumors was accomplished by either magnetic bead sorting of
the CD133+ population or by using the Hydrodynamic Focusing Bioreactor (HFB). To
determine if these methods produced the same results, different isolation methods were
compared and found that the response to the drugs was not statistically significant (Figure 3).
However, it was also determined that in order to obtain the necessary number of sub-confluent
plates of cells to be used in a magnetic bead sort of CD133+ cells useful to perform a
chemosensitivity assay it would take around two months of tissue culture vs. the seven days
process when using the HFB (45).

Figure 3. Drug Response to: HFB vs. MACSorted CD133 Isolation.
Same GBM cell line was used to compare the CD133 population of cells isolated by HFB vs. MACSorted
CD133 Microbeads kit. Each assay was plated with 1x104 cells per well. All assays were treated with one
hour pulse of chemotherapeutic agents then analyzed 24 hours later with MTT. P-value was greater than
0.5 when comparing the assays.
14

After bulk of tumor cells and CSLCs of each primary patient cell line were tested to
determine the response to the various drugs by MTT assay, the samples were analyzed by
calculating the percentage of cellular viability against the control using the following formula:
("    / #
% %& #

'  #

  " ) ∗ 100 =
 

Percent of non-viable cells were calculated using the following formula: 100 −
% %& # = % # ). Drug response was reported by assigning samples in which it
was found that there was between 60-100% Cell Kill to a responsive category; followed by 3059.9% Cell Kill to be intermediate responsive; and 29.9-0% to be non-responsive.
Standard deviation was calculated off of the mean absorbance of the MTT assay for each
treatment and multiplied by 100 to get the percent standard deviation. If this number was greater
then 5% one value would be removed using the student t-test. If less than 5% standard deviation
was still not achieved then whole test would be run again.
Disease outcomes were correlated to the determination of chemosensitivity to the specific
chemotherapy drug that was administered to the patient to determine clinical correlation with the
in vitro chemosensitivity assay.

Chemotherapy Sensitivity Assay Validation
This assay has been recently validated in compliance with CLIA regulations
(42CFR493.1291 (3)). Accuracy and precision were assayed by a minimum of three (3) repeats
of the chemotherapy sensitivity assay, with three (3) established cell lines with unique
chemotherapeutic response profiles covering the spectrum of the detectable range of <10% to
100% cell viability.
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Quantitative agreement, with less than 30% standard deviation, of cell viability for cell
line HEK293, less than 16% standard deviation for cell line SW480, and less than 18% standard
deviation cell viability for cell line DU145 were the intended goals. These standard deviations
were determined by assaying growth control plates for the established cell lines which were used
to ascertain their base mitochondrial activity in relation to cell viability.
Growth control plates were established by plating 10,000 cells/ml of each cell line in a
series of wells. These plates followed the same incubation periods and were treated the same as a
regular assay as outlined in the chemotherapy sensitivity assay, except they were not treated with
any chemotherapeutics. Absorbance readings were taken and from those, percent cell viability
was calculated. The difference in the range of cell viability determined the acceptable percent
standard deviation for that cell line.
Repeatability was measured by the performance of two runs of the assay for each
chemotherapeutic (dosage and infusion rate) by the same person. Agreement between these two
runs is expected to be less than the acceptable standard deviation for that cell line determined by
the growth control plate.
Reproducibility was measured by the performance of the test being analyzed on
discontinuous days by a different person and contributed to the overall accuracy of the test.
Within-run repeatability was assessed by the four (4) repeats per chemotherapeutic per
assay that are standard to the chemotherapy sensitivity assay. The standard deviation of these
four repeats shall be no greater than 5%. One outlier per the four repeats per chemotherapeutic
can be thrown out per standard operating procedure for the chemotherapy sensitivity assay and
still achieve statistical significance.
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Repeatability: 99.5% of all repeats matched within the acceptable standard deviation.
Reproducibility: 95.5% of all repeats matched within the acceptable standard deviation. WithinRun Repeatability: 99.7% of all repeats per chemotherapeutic per run matched within a 5%
standard deviation.
Analytical sensitivity was tested by treating 10,000 cells/ml with 100µ l of 100% ethanol.
Ethanol, used as a positive control in the chemotherapy sensitivity assay, will kill the majority of
the living cells. The resultant absorbance readings showed that cell viability ranged from 1.2% to
11.2% across varying cell lines showing that chemotherapy sensitivity assay can detect living
cells in the range of 120 – 1,120 cells/ml. Thus a range of <10% cell viability is the minimum
limit of the chemotherapy sensitivity assay's sensitivity to be reported on diagnostic tests.
Analytical specificity was tested by attempting chemotherapy sensitivity assay on nonneoplastic cells. The percentage of normal stem cells that grew or survived during the initial
growth period prior to chemotherapy analysis was too low to perform the chemotherapy
sensitivity assay showing that only neoplastic cells can survive the culture growth period in
testable numbers.
Robustness of this lab developed test was assessed by observing the culture growth of
CNS tumor tissue samples stored in varying media and conditions. This condition was successful
in producing enough cells for analysis: RPMI-1640 + 10% FBS + 2% P/S stored at room
temperature. These conditions were deemed unsuccessful for chemotherapy sensitivity assay
analysis: RPMI-1640 + 10% FBS + 2% P/S stored at 4ºC for up to 2 hrs, Saline stored at room
temperature, and Ethanol stored at room temperature.
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Figure 4. Robustness Testing on Primary Tumor Tissue.
A) Media: RPMI + 10% FBS + 2% P/S Storage condition: Room temp. Growth period: expected growth
after 7-day incubation. B) Media: RPMI + 10% FBS + 2% P/S Storage condition: 4ºC for 2 hrs. Growth
period: no growth after 7-day incubation. C) Media: Saline Storage condition: Room temp for 2 hrs.
Growth period: slow growth after 7-day incubation. D) Media: Ethanol Storage condition: Room
temp for 2 hrs. Growth period: slow to no growth after 7-day incubation.

Reportable range was confirmed by testing cell lines ranging from <10% viability to
100% viability and unique chemotherapeutic response profiles were generated for each cell line.
Cell lines successfully repeated among these ranges.

18

CONCLUSIONS
The drug response assay tested for both the sensitivity to standard-of-care drugs on the
overall tumor (Bulk) and the CSLC population. By challenging these cells with the different
chemotherapeutic agents the test was able to determine ineffective drugs that could be excluded
from the panel of drugs used by the treating physician.
This study investigated 4 cases of CNS malignant tumors, two Ependymoma and two
Glioblastoma. When these cases were treated with standard-of-care chemotherapy drugs the
tumors should have responded in a similar fashion, however, the data accrued in this study shows
that patients had better outcomes when treated with effective chemotherapies against CSLC. It is
important to note that response of CSLCs to the treating chemotherapies indicated the patient
disease outcome in both cases. While many other CNS cases have been studied with this method,
the data relative to these cases is being analyzed and it will be the subject matter of a future
publication.
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ABSTRACT
Administration of ineffective anticancer therapy is associated with unnecessary toxicity
and development of resistant clones. Cancer stem-like cells (CSLCs) resist chemotherapy,
thereby causing relapse of the disease. Thus, development of a test that identifies the most
effective chemotherapy management offers great promise for individualized anticancer
treatments. This study was designed to investigate an ex vivo chemotherapy sensitivity assay,
which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of
chemotherapy agents. Two patients, a 21-year old male (patient 1) and a 5-month female (patient
2), affected by anaplastic WHO grade-III Ependymoma were screened using the chemotherapy
sensitivity assay. Patient 1 was found sensitive to the combination of Irinotecan and
Bevacizumab, which resulted in a prolonged disease progression free period of 18 months.
Following recurrence, the combination of various chemotherapy drugs was tested again with the
chemotherapy sensitivity assay. This study found that benzyl isothiocyanate (BITC) greatly
increased the chemosensitivity of the Ependymoma cells to the combination of Irinotecan and
Bevacizumab. After patient 1 was treated for two months with Irinotecan, Bevacizumab and
supplements of cruciferous vegetable extracts containing BITC, 50% tumoral regression was
achieved in comparison with pre- chemotherapy sensitivity assay scan as evidenced by MRI.
Patient 2 was found resistant to all treatments tested and following 6 cycles of Vincristine,
Carboplatin, Cyclophosphamide, Etoposide, and Cisplatin in various combinations, the tumor of
this patient rapidly progressed and proton beam therapy was recommended. As expected animal
studies conducted with patient derived xenografts treated with chemotherapy sensitivity assay
screened drugs recapitulated the clinical observation. This assay demonstrates that patients with
the same histological stage and grade of cancer may vary considerably in their clinical response,
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suggesting that chemotherapy sensitivity assay testing which measures the sensitivity of CSLCs
as well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more
effective and personalized anticancer treatments in the future.
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INTRODUCTION
Although Ependymomas are the third most common type of brain tumor in children
(following Astrocytoma and Medulloblastoma), they are relatively rare, with approximately 200
cases diagnosed in the US each year (59,60). They account for 60% of all intramedullary tumors
and 50% arise in the filum terminale (61).
The treatment of Ependymoma can be challenging. The initial standard treatment for
Ependymoma is surgery often followed by radiation therapy and chemotherapy. Although
chemotherapy has been used extensively in children with Ependymoma, there is little clinical
evidence that chemotherapy improves survival of children with this type of tumor.
Chemotherapy is often reserved for patients with residual tumor after surgery and for children
younger than 3 years of age in an attempt to delay radiation therapy (62).
It is not entirely clear why there is not an improved survival with chemotherapy, but it is
known that resistance to a variety of commonly used chemotherapeutic agents is common in
Ependymoma (63). Therefore investigation and development of novel strategies and integrated
therapies are required to find more effective treatments for this type of tumor.
Patients with the same stage and grade of cancer may vary considerably in their clinical
response and toleration of chemotherapy. Ineffective anticancer therapy can result in unnecessary
toxicity and the development of resistant clones. The surviving cancer cells are often more
resistant to therapy. Many attempts have been made over the years to develop an ex-vivo anticancer test that could help discern the best treatment options for each individual patient while
minimizing toxicity.
Animal xenograft models have shown that only a subset of cancer cells within each tumor
is capable of initiating tumor growth. This capability has been shown in several types of human
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cancers, to include Ependymoma (64). This pool of cancer cells is operationally defined as the
‘‘Cancer Stem-Like Cell’’ (CSLC) subset. According to the ‘‘cancer stem-like cell’’ theory,
tumors are a complex, growing population of abnormal cells originating from a minority of
CSLCs. These cells maintain stem-like characteristics in that they proliferate very slowly and
have an inherent capacity to self-renew and differentiate into phenotypically heterogeneous,
aberrant progeny (45,65-67). Unlike the bulk of tumor cells, CSLCs resist chemotherapy and
radiation therapy and are responsible for tumor relapse and metastasis (66,67).
Some Ependymoma express various markers of stemness, including CD133. In addition,
relapsed tumors exhibit a gene expression signature constituted by up-regulated genes involved
in the kinetochore (ASPM, KIF11) or in neural development (CD133, Wnt and Notch pathways)
(68).
Targeting CSLCs in addition to the bulk of other cancer cells within a tumor is a new
paradigm in cancer treatment. This recent study shows that a Hydrodynamic Focusing Bioreactor
(HFB) (Celdyne, Houston TX) selectively enriches CSLCs from cancer cell lines that can be
used in a chemosensitivity assay (45). Further, using this strategy to optimize the enrichment of
CSLCs from tumor biopsies has become essential to the development of the chemotherapy
sensitivity assay, which measures the response of CSLCs and the bulk of tumor cells to
chemotherapy to determine the most effective combination of anticancer drugs for malignant
tumors of the nervous system.
In this study it is reported for the first time, an investigation using the chemotherapy
sensitivity assay to measure the sensitivity and resistance of CSLCs and bulk of tumor cells. It
was performed on two biopsies cultured from human Ependymoma. These tumors were
challenged with several chemotherapy agents which were also correlated to the response of
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animal xenografts treated with the predicted drugs and to the clinical response of the treated
patients.
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MATERIALS AND METHODS
Patients
Case 1 is a 21-year-old male patient diagnosed with intradural, intramedullary, and
extramedullary anaplastic diffuse spinal Ependymoma, WHO grade III. Case 2 is a 5-month old
female patient diagnosed with anaplastic WHO grade III Ependymoma. The chemotherapy
sensitivity assay was performed after obtaining patient’s or guardian’s written informed consent
in accordance with the ethical standards of the Helsinki Declaration (1964, amended most
recently in 2008) of the World Medical Association. Any information, including illustrations, has
been anonymized. Marshall University Institutional Review Board (IRB) has approved this
research under the protocol #326290. Participants or guardians of participant (in case of a child
participant) provided their written consent on an IRB approved informed consent form to
participate in this study after being educated about the research protocol. Ethics committees/ IRB
at Marshall University approved this consent procedure. For children participants to the study,
written informed consent was obtained from the next of kin, caretakers, or guardians on behalf of
the minors/children enrolled in the study.

Single Cell Suspension and Primary Cell Culture
Single-cell suspensions from the Ependymoma biopsies were prepared using the
gentleMACS Dissociator (Miltenyi, Auburn, CA), and C Tubes using a standardized, semiautomated protocol based on a combination of mechanical tissue disruption and incubation with
a 50% solution of a 0.025% Trypsin and Accutase (Innovative Cell Technologies, San Diego,
CA). Cells were serially plated in 24-well, 12-well, 6-well, 10-cm treated dishes and cultured to
subconfluence in RPMI-1640 medium supplemented with 5% irradiated, heat inactivated,
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defined fetal bovine serum (Thermofisher/Hyclone), and 50 U of penicillin and 5 mg of
streptomycin/mL of medium (Thermofisher/Mediatech).

Reagents
Benzyl isothiocyanate (BITC) was purchased from Sigma Chemical Co. (St. Louis, MO).
Bevacizumab (Avastin), Cisplatin, Oxaliplatin, Arabinoside-C, VP-16, Irinotecan (Camptosar,
CPT-11), Busulfan, Methotrexate, were acquired as clinical grade chemotherapy agents from
Edwards Cancer Center and St. Mary’s Hospital.

Three-Dimensional Bioreactor CSCs Culture
A Hydrodynamic Focusing Bioreactor (HFB) (Celdyne, Houston TX) was used as
previously described to selectively proliferate CD133 (+) cancer stem-like cells (45). Culture
media, oxygenation, speed, temperature and CO2 were kept constant for ten days. Cells were
counted and 1x10 cells were placed in the rotating vessel set at 25 rpm with airflow set at 20%.
Cells were then removed and counted again using trypan blue exclusion to determine cellular
viability and cell number and plated in 96 wells for chemosensitivity testing. The cells were also
incubated with florescent antibodies for phenotypic characterization (45).

Cell Sorting
Up to 1x10 cells were sorted by a magnetic-activated cell sorting (MACS) system,
which consists of magnetic beads conjugated to an antibody against CD133 (Miltenyi, Auburn,
CA). In brief, cells were harvested using 0.25% trypsin, pelleted and labeled with CD133/1
biotin and CD133/2-PE. Cells were washed and labeled with anti-biotin magnetic beads, and
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then passed through a magnetic column where CD133 (+) cells were retained, while unlabeled
cells passed through the column. The CD133 (+) retained cells were eluted from the columns
after removal from the magnet. Positive and negative cells were then analyzed by FACS for
purity.

Flow Cytometry Studies
Cells were analyzed by the antigenic criteria using anti-CD34 (Milteny Biotech, Auburn,
CA), -CD38 (Milteny Biotech, Auburn, CA), -CD44 (BD Bioscience, Sparks, MD), -CD117
(Milteny Biotech, Auburn, CA), -CD133/2 (prominin1) (Milteny Biotech, Auburn, CA), -Oct3/4
(BD Bioscience, Sparks, MD), and –Nanog (BD Bioscience, Sparks, MD). Briefly, cells were
detached using 0.02% EDTA in PBS and pelleted (10 min at 1,000 rpm), washed in 0.1% BSA
in 1X PBS at 4°C and incubated in a solution of 1 mg antibody +9 mL 0.1% BSA in 1X PBS.
Cells were washed in the same solution once and were analyzed using a C6 Accuri flow
cytometer (BD Biosciences, San Jose, CA).

Chemotherapy Sensitivity Assay
Sensitivity to chemotherapy was assessed using a viability assay (WST8) on 1x10³ cells
plated in five replicas into 96-well plates. Briefly, equal number of bulk of tumor cells grown in
monolayer and CSLCs grown in the bioreactor were counted and seeded separately in 96-well
dishes and incubated at 37°C for 24 hours. The cells were then challenged with a one-hour pulse
of a panel of anticancer drugs as chosen by the oncologist to mimic the average clinical
chemotherapy infusion schedule.
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To study the effect of BITC on chemosensitization of cancer cells to chemotherapy drugs,
the cells were treated with an hour pulse 5–30 mM BITC followed by an hour of the various
anticancer drugs. Each anticancer drug was tested in a range of doses including the clinically
relevant dose.
A WST8 assay was performed 48 hours following chemotherapy treatment to assess cell
viability as previously described (69). A dose response chart was developed in which samples
were scored as responsive (0–30% cell survival), intermediate (30–60% cell survival), and nonresponsive (60–100% cell survival).

Limiting Dilution Tumorigenic Assay in Immune Deficient Mice
A range of 1x10²; 1x10³; 1x10⁴; and 1x10⁵ Ependymoma cells from Patient 1 were
injected subcutaneously in five athymic immunodeficient nude nu/nu mice per group. Briefly, an
equal number of parental bulk of tumor cells grown in 2D monolayer, CD133 (+) threedimensionally grown in the hydrofocusing bioreactor, and CD133 (+) MACSorted CSLCs were
injected with 100 mL of matrigel in the flank of NOD-Scid mice and compared to the growth of
CD133 negative cells for three months.

Animal Study
All animal studies have been conducted following approval from the Marshall University
IACUC, protocol #373017. The effects of chemotherapies screened in vitro by the chemotherapy
sensitivity assay were tested on human tumor biopsies that were xenografted in the flank of a
NOD-Scid mouse model. 1x10 Ependymoma cells were mixed to 100 uL of matrigel (BD
Biosciences, San Jose, CA) injected subcutaneously in the flank of ten athymic, NOD.Cg- Prkdc
29

Scid ll2rgtm1wjl/SzJ immunodeficient mice (NOD-Scid)/group and were grown for 10 weeks or
until 100 mm³. Mice were randomized in different treatment and control groups and
chemotherapy was administered by intraperitoneal (i.p.) injections in 200 uL as follows in a
period of four weeks: 1) Group #1, Control group with primary tumor cells injected into flank
and receiving i.p. sterile saline injections. Group #2, Experimental group injected i.p. with the
least effective chemotherapy as determined by the in vitro chemotherapy sensitivity assay. Group
#3, Experimental group injected i.p. with the most effective chemotherapy as determined by the
in vitro chemotherapy sensitivity assay. Group #4, Experimental group injected i.p. with the
second most effective chemotherapy as determined by the in vitro chemotherapy sensitivity
assay. Group #5, Experimental group injected i.p. with the most effective combinatorial
chemotherapy as determined by the in vitro chemotherapy sensitivity assay.
Chemotherapy doses for the animal study were calculated using a body surface area
(BSA) normalization method (70) from the clinical dose and verified according to doses
previously determined by a literature search.
Animals were euthanized following the current guidelines established by the latest Report
of the AVMA Panel on Euthanasia using CO2 inhalation and asphyxiation followed by cervical
dislocation.

Statistical Analysis
Statistical analysis was performed using the IBM SPSS statistical software. The results
for each variant in the different experimental designs represent an average of three different
experiments. The data of five measurements were averaged; the coefficient of variation among
these values never exceeded 10%. Mean values and standard errors were calculated for each
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point from the pooled normalized to control data. Statistical analysis of the significance of the
results was performed with a one-way ANOVA. P values of less than 0.05 were considered
statistically significant.
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Figure 5. MRI Images and H&E Staining of the Anaplastic Ependymoma Case 1 at Presentation.
A) Magnetic Resonance Imaging (MRI) of the cervical spine showing the presence of an enhancing mass,
which extends from mid C5 to inferior C7 (4.5 in length x 1.0 x 2.0 in cephalocaudal and anteroposterior
dimension) and causing cord compression.
B) MRI of the thoracic spine showing an enhancing lesion at T2–3 (1.5 in length x 0.6 x 0.6 cm in
anteroposterior and transverse dimension) with several other smaller nodular masses, best seen on the T2
weighted sequence, which extended throughout the thoracic level to T11.
C) Hematoxylin and Eosin staining of a tumor section showing an overall predominant dense cellular
component, with primitive nuclear features, mitotic activity, necrosis and vascular proliferation. The
presence of well formed, obvious perivascular pseudorosettes (with vasocentric pattern, perivascular
nuclear-free zones, and classic thin glial processes radiating to/from the vessel wall) were found
supportive of the diagnosis of intradural, extramedullary anaplastic diffuse spinal Ependymoma, WHO
grade III. doi:10.1371/journal.pone.0105710.g001
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RESULTS
Ependymoma Patient 1
A physically active 17-year-old male presented in October 2005 with paresthesia in his
feet and a rather severe perceptive loss. This became progressively worse in December 2005
going up his legs with rather severe numbness in the right leg and pain in his left leg, from the
mid-thigh down to the mid-calf medially. On examination he had no focal weakness throughout
his upper and lower extremities. He had hypoalgesia with partial sensory level in the upper
thoracic spine down. He also had severe proprioception loss in his feet and toes. Magnetic
resonance imaging (MRI) of the cervical spine showed the presence of an abnormal enhancing
mass, which extended from mid C5 to inferior C7 (4.5 in length x 1.0 x 2.0 in cephalocaudal and
anteroposterior dimension) that caused cord compression (Figure 5A). MRI of the thoracic spine
showed an enhancing lesion at T2–3 (1.5 in length x 0.6 x 0.6 cm in anteroposterior and
transverse dimension) with several other smaller nodular masses, best seen on the T2 weighted
sequence, which extended throughout the thoracic level to T11 (Figure 5B).
The patient received a laminectomy in December 2005 at C5, C6, and C7 with partial
resection of the tumor under microscope using microsurgical techniques. Following surgery, the
patient was treated with radiation and temozolomide. Morphological analysis of the histology
sections stained with Hematoxylin & Eosin showed an overall predominant dense cellular
component, with primitive and pleomorphic nuclei, increased mitotic rate and apoptosis, and foci
with microvascular proliferation. The presence of well formed, obvious perivascular
pseudorosettes (with vasocentric pattern, perivascular nuclear-free zones, and classic thin glial
processes radiating to/from the vessel wall) were found supporting the diagnosis of anaplastic
diffuse spinal Ependymoma, WHO grade III.
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Figure 5C shows the hematoxylin and eosin staining of a tumor section at diagnosis in
2005. Sections of the tumor were evaluated by immunoperoxidase techniques with appropriate
staining control sections. The tumor showed positive staining with antibodies to neuron specific
enolase, vimentin, S-100, and GFAP. Weak staining occurred with the antibodies against actin.
Focal staining occurred with antibodies to epithelial membrane antigen, cytokeratin AE1/AE3,
and synaptophysin. The tumor was negative for leukocyte common antigen, desmin, and
myogenin. In addition, a section stained with PAS showed a focal PAS-positive fibrillar material.
Sections and tumor block were also sent to the Biopathology Center (BPC) of the Children’s
Oncology Group (COG) where two neuropathologists independently reviewed the case and
confirmed the diagnosis of Anaplastic Ependymoma, WHO grade III.
Following recurrence and progression, the patient received complex chemotherapy
regimen in January 2006 and March 2006 with Cyclophosphamide, Thalidomide, Celecoxib
followed by Etoposide, Thalidomide and Celecoxib. Chemotherapy treatment was concluded in
September of 2006, but in August of 2007 patient had tumor regrowth at T7–T8 for which he
underwent robotic radiosurgery treatment. The patient had another debulking surgery in April of
2008, but later in December of 2008 he had progressive numbness in his legs along with back
pain with MRI showing recurrence in the surgical area (Figure 6A) as well as the lumbar spine.
He was then treated again with Temozolomide, but had no response to treatment.
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Figure 6. MRI Images of Cervical and Thoracic Spine of Ependymoma Case 1.
A) 2009 MRI of the cervical spine showing recurrence in the surgical area. B) 2009 MRI of the thoracic
spine showing progression of the main lesion measuring 23.9 mm, and the appearance of several other
smaller lesions. C and D) 2010 MRI of the cervical and thoracic spine showing tumor regression
following a treatment with Irinotecan and Bevacizumab. doi:10.1371/journal.pone.0105710.g002
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In March 2009 because of progression of the disease he had a thoracic laminectomy and
resection of the intradural intramedullary tumor. He had severe spinal compression and began
having weakness in his legs. Due to further recurrence, the patient then had another debulking
surgery in July of 2009. He also received Oxaliplatin and Etoposide treatment in July and August
2009, but the tumor progressed even more (Figure 6B). Appropriate informed consent was
signed and at the time of the debulking surgery of July 2009, a sterile biopsy was taken to assess
the sensitivity of the tumor cells (bulk of tumor and CSLCs) toward standard-of-care
chemotherapy drugs using the chemotherapy sensitivity assay. The biopsy was placed in RPMI1640 sterile media and tissue was dissociated in the laboratory into a single-cell suspension with
the use of a GentleMACS tissue dissociator (Miltenyi, Aubourn, CA). The single-cell
Ependymoma suspension was plated in RPMI-1640 in the presence of 5% irradiated, heat
inactivated, defined fetal bovine serum, streptomycin and penicillin and cells were cultured as a
monolayer for 15 days. Cells were immunophenotyped by flow cytometry using antibodies
against CD34, CD38, CD44, CD117, CD133, OCT3/4, and Nanog.
The Ependymoma cells were found positive to OCT3/4 (2.73%), Nanog (0.95%), CD133
(49.93%), CD117 (36.81%), and CD44 (20.39%) when compared to an isotype control antibody
(Figure 7 A-E). A double staining of CD34 and CD38 showed the presence of 1.88% of the cells
CD34+/CD38+, and 78.4% CD34+/CD38- cells (Figure 7F). To expand the CSLC population of
CD133+ cells from the Ependymoma primary culture, the Ependymoma cells were cultured as
previously described (45). 1x10 of the Ependymoma cells from a monolayer primary culture
were grown for ten days using Hydrodynamic Focusing Bioreactor (HFB) (Celdyne, Houston,
TX) (45). The Ependymoma cells cultured in the bioreactor formed cell clusters (Figure 8A)
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which were expanded 14.7 fold (Table 1) and appeared to be 95.93% CD133 positive after 10
days of culture in the bioreactor (Figure 7 C, enriched CSLCs).
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Figure 7. Characterization of the Primary Ependymoma Cell Culture and of the Enriched CSLCs of Case
1.
A-F) Immunophenotype conducted using: A) OCT3/4 antibody; Left panel: isotype antibody (bulk of
tumor cells); Center panel: specific antibody (bulk of tumor cells); Right panel: specific antibody
(enriched CSLCs). B) Nanog antibody; Left panel: isotype antibody (bulk of tumor cells); Center panel:
specific antibody (bulk of tumor cells); Right panel: specific antibody (enriched CSLCs). C) CD133
antibody; Left panel: isotype antibody (bulk of tumor cells); Center panel: specific antibody (bulk of
tumor cells); Right panel: specific antibody (enriched CSLCs). D) CD117 antibody; Left panel: isotype
antibody (bulk of tumor cells); Center panel: specific antibody (bulk of tumor cells); Right panel: specific
antibody (enriched CSLCs). E) CD44 antibody; Left panel: isotype antibody (bulk of tumor cells); Center
panel: specific antibody (bulk of tumor cells); Right panel: specific antibody (enriched CSLCs). F)
Double labeling with CD34 and CD38 antibodies; Panel on left: isotype antibody (bulk of tumor cells);
Center panel: specific antibody (bulk of tumor cells); Panel on right: specific antibody (enriched CSLCs).
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Figure 8. CD133 (+) Ependymoma Cells from Case 1 Grown in a Hydrofocusing Bioreactor form
Xenografts in nude Mice.
A) Contrast phase image of a cluster of enriched CSLCs following seven-days of culture in a
hydrofocusing bioreactor. B) Immunodeficient nude mice (nu/nu) injected with 1x10² Ependymoma cells
MACSorted CD133(+) cells or CD133(+) Ependymoma cells grown in the hydrofocusing bioreactor,
with the aid of 100 mL of matrigel in the flank formed a tumor within three months compared to
CD133(2) cells. doi:10.1371/journal.pone.0105710.g003

Table 1. Enrichment of CD133+ CSLCs using a hydrofocusing bioreactor.

To verify the tumor-initiating capacity of the HFB grown cells, five immune deficient
nude mice/group were injected with a range of 1x10², 1x10³, 1x10⁴, and 1x10⁵ cells grown in the
HFB (96% CD133+) and compared their growth to an equal number of CD133(+) MACSorted
cells and CD133(2) cells for three months. It was observed that both 1x10² MACSorted CD133
(+) cells or the CD133 (+) from the bioreactor grew in all the immune deficient mice injected
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and formed a palpable tumor within 12 weeks (Figure 8B). To perform the chemotherapy
sensitivity assay a comparable number of cells (1x10⁵) from the bulk of tumor cells grown as a
2D monolayer or CSLCs enriched in the bioreactor (45) were separately plated into 96 wells
plates (n-5 replicas) and were treated for an hour with a series of anticancer drugs at a range of
concentrations including the clinically relevant dosage (Table 2). Chemotherapy sensitivity assay
was performed using a panel of drugs comprised of Cisplatin, Oxaliplatin, Arabinoside-C, VP16, Busulfan, Methotrexate, Irinotecan, and Bevacizumab as chosen by the treating oncologist.
Sensitivity to chemotherapy was assessed at 48-hours by WST8 viability assay. It was
categorized as follows based on the percentage of non-viable cells: responsive (0–40% cell
survival), intermediate (40–70% cell survival), and non-responsive (70–100% cell survival). The
WST8 assay was conducted three separate times with n=5 well replicas/drug/dose each time.

Table 2. Clinical dose and calculated in vitro doses of the various chemotherapies.

Results of the chemotherapy sensitivity assay (Figure 9) showed that the Ependymoma
cells grown in monolayer and representing the bulk of tumor cells were sensitive to clinically
relevant doses of Cisplatin, Irinotecan, Busulfan, and a combination of Irinotecan and
Bevacizumab in a statistically significant manner (p< 0.05). Interestingly, the CSLCs were
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sensitive to a combination of Irinotecan and Bevacizumab (p< 0.05), intermediately sensitive to
Cisplatin, and Irinotecan, but not sensitive to Busulfan. On the other hand, both the CSLCs and
the bulk of tumor cells were not responsive to Methotrexate, Oxaliplatin, Arabinoside-C, and
VP-16 (Figure 9). Because of the lack of response to an Oxaliplatin and Etoposide management
given in August 2009 (Figure 6B) (which was started prior to receiving the results from the
chemotherapy sensitivity assay), in October 2009 the patient underwent a treatment with
Bevacizumab and Irinotecan, which was administered every two weeks for six months. In a
follow-up MRI scan in May 2010 the patient showed initial disease regression remaining free
from disease progression for 18 months (Figure 6C and D). This corresponded to the longest
disease progression free period observed in this patient without major de-bulking surgery.
Recurrence of tumor growth after 18 months of disease free progression led us to explore novel
therapeutic approaches for the treatment of this patient’s cancer. In this regard, combination
chemotherapy was investigated in order to identify natural compounds that may increase the
clinical efficacy of anticancer drugs.
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Figure 9. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to Chemotherapy of
Cancer Cells or CSLCs of Ependymoma Case 1 Using a WST-8 Assay.
Bulk of tumor cells or CSLCs were plated with 1x10³ cells in each well of a 96-well plate. The treatments
were replicated five times in 96-well plates and were challenged for a one-hour pulse with a panel of
anticancer drugs indicated by the oncologist. A WST-8 assay was performed 48-hours following
chemotherapy treatments to assess cell viability. The data above is plotted in bar graph and results were
determined as responsive (0–40% cell viability), moderately responsive (40–70% cell viability), and nonresponsive (70–100% cell viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with
respect to negative untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the
bottom of the diagram. Statistical analysis of the results was performed using one-way ANOVA.
Asterisks indicate p values of less than 0.05. doi:10.1371/journal.pone.0105710.g004

Benzyl isothiocyanate (BITC) has been shown (71,72) to increase the chemosensitivity of
cancer cells. This study recently observed (Figure 10) that BITC increases specifically the
chemosensitivity of CD133 positive cancer cells. Because the primary Ependymoma cells of
Patient 1 displayed a high percentage of cells positive to CD133, the hypothesis that BITC could
increase their chemosensitivity to Irinotecan and Bevacizumab was tested. Increasing
concentrations of BITC ranging from 2.5 mM to 20 mM decreased the viability of CD133(+)
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Ependymoma cells of Patient 1 from 90% to 62% in a statistically significant manner (Figure
11A). Chemotherapy sensitivity assay also determined that the combination of Irinotecan and a
non-toxic concentration of 10 mM BITC reduced the viability of the Ependymoma cells from
60% to 40% (over 40% more chemosensitive compared to non BITC treated cells) (Figure 11B).
Additionally, the combination of Irinotecan and Bevacizumab with BITC reduced even further
the viability of the Ependymoma cells to 30% (Figure 6B). The patient was treated with
Irinotecan and Bevacizumab, but this time with the combination of two capsules/day of a Triple
Action Cruciferous Vegetable Extract containing high concentration of BITC (LifeExtension,
http:// www.lef.org), for two months. Following the combination therapy of Irinotecan,
Bevacizumab and the supplement of cruciferous vegetable extract there was a 4 cm regression
(which corresponds to a 50% regression) of the lesions in the thoracic and the cervical area
[compare Figure 6C (at recurrence) to Figure 11D (following therapy)]. Additionally, it was
reported that the patient was able to tolerate the entire course of Irinotecan and Bevacizumab
chemotherapy regimen with less fatigue and better tolerance to cold.
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Figure 10. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to BITC and
Chemotherapies of Cancer Cells or CSLCs of Ependymoma Case 1.
1x10³ bulk of tumor cells or CSLCs plated in five replicas into 96-well plates were treated with 10uM of
BITC for 24 hours before being challenged for a one-hour pulse with CPT-11, Avastin or a combination
of the two. A WST-8 assay was performed 48 hours following BITC treatments to assess cell viability.
Data is plotted in bar graph as responsive (0–40% cell viability), moderately responsive (40–70% cell
viability), and non-responsive (70–100% cell viability). Light grey bars represent sensitivity of CSLCs to
chemotherapy with respect to negative untreated control cells. Dark grey bars represent sensitivity of bulk
of tumor cells to chemotherapy with respect to negative untreated control cells. Anticancer drugs tested
indicated at the bottom of the diagram. Statistical analysis of the significance of the results was performed
with a one-way ANOVA. Single asterisks indicate p values of less than 0.05. Double asterisks indicate p
values of less than 0.01.
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Figure 11. Diagram of Chemotherapy Sensitivity Assay and MRI Images of Cervical and Thoracic Spine
following Integrated Therapy of Ependymoma Case 1.
A) 1x10³ CSLCs plated in five replicas into 96-well plates were challenged for a one-hour pulse with 2.5,
10, and 20 mM BITC. A WST-8 assay was performed 48 hours after treatments to assess cell viability. B)
1x10³ CSLCs plated in five replicas into 96-well plates were challenged for a one-hour pulse with 10 mM
BITC followed by a one-hour pulse with 0.5 mM CPT-11. A WST-8 assay was performed 48 hours
following chemotherapy treatment to assess cell viability. Data is plotted in bar graph as responsive (0–
40% cell viability), moderately responsive (40–70% cell viability), and non-responsive (70–100% cell
viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with respect to negative
untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to chemotherapy with
respect to negative untreated control cells. Statistical analysis of the significance of the results was
performed with a one-way ANOVA. Asterisks indicate p values of less than 0.05. C) 2012 MRI of the
cervical and thoracic spine showing recurrence after an 18 months progression free period. D) 2012 MRI
of the cervical spine showing marked tumor regression of the thoracic spine lesion following combined
treatment with Irinotecan (CPT11), Bevacizumab (Avastin), and BITC supplementation.
doi:10.1371/journal.pone.0105710.g005
47

The efficacy of chemotherapies screened in vitro by the chemotherapy sensitivity assay
were tested on the Ependymoma cells of Patient 1 that were xenografted in a NOD-Scid mouse
model (Figure 12 A and B). Ten athymic NOD-Scid mice were injected in the flank with 1x10
Ependymoma cells mixed to 100 uL of matrigel (BD Biosciences, San Jose, CA) and tumors
were grown for ten weeks or until 100 mm³. Randomized mice were treated with weekly
intraperitoneal (i.p.) injections of the different treatment arms for four weeks and were observed
for four more weeks. Group #1 serving as a control received i.p. sterile saline injections. Groups
#2–5 were the experimental groups, which received i.p. injections of the least effective
chemotherapy, or the most effective, the second most effective, and the most effective
combinatorial chemotherapy, as determined by the in vitro chemotherapy sensitivity assay.
Interestingly, the tumor xenografts in the Scid mice injected with the least effective
chemotherapy as determined by the in vitro chemotherapy sensitivity assay grew faster than
saline control injected mice (Figure 12A). As expected, tumor regression was observed in Scid
mice treated with the most effective, the second most effective, and the most effective
combinatorial chemotherapy as determined by the in vitro chemotherapy sensitivity assay,
confirming the clinical observation that Irinotecan and Bevacizumab are more effective
anticancer drugs in this individual patient. Mice weight was measured weekly (Figure 12B).
The hypothesis was tested further by mice that were failing a chemoresistant treatment
could be rescued by switching them to a more sensitive treatment as determined by the in vitro
chemotherapy sensitivity assay. Mice that were failing an Oxaliplatin therapy regimen were
taken off Oxaliplatin at week 16 and were treated for four weeks with a combination of
Irinotecan and Bevacizumab. As expected, mice treated with Irinotecan and Bevacizumab
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showed a regression of the xenografted tumor compared to the control mice injected with saline
solution (Figure 12C) confirming once again the previously observed clinical data.
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Figure 12. Mean Tumor Volume and Mean Tumor Weight of Patient Derived Xenografts (Ependymoma
Case 1) Treated with i.p. Injection of Anticancer Drugs.
A) Line diagram of the mean volumes in mm³ (±SD) from week 6–16 of ten patient derived xenografted
tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs. The mean
tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was performed.
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On the right are indicated the different treatment arms. PBS: saline solution, negative control. OXA
(Oxaliplatin); Avastin (Bevacizumab); CPT-11 (Irinotecan); CDDP (Cisplatin). B) Line diagram of the
mean weight in grams (±SD) of ten NOD-Scid mice-bearing patient derived xenografted tumors
following four weeks of treatment with various anticancer drugs. The mean tumor weights are indicated
on the ordinate. Asterisks indicate weeks in which treatment was performed. On the right are indicated the
different treatment arms. PBS: saline solution is negative control. OXA (Oxaliplatin); Avastin
(Bevacizumab); CPT-11 (Irinotecan); CDDP (Cisplatin). C) Line diagram of the mean volumes in mm³
(±SD) from week 16 to 20 of the ten patient derived xenografted tumors in NOD-Scid mice that failed
Oxaliplatin therapy (weeks 6–16 in panel A), following three weeks of treatment with Irinotecan and
Bevacizumab. The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which
treatment was performed. On the right are indicated the different treatment arms. PBS: saline solution,
negative control. OXA (CPT11+Avastin): mice that failed Oxaliplatin and were then treated with
Irinotecan and Bevacizumab. D) Line diagram of the mean weight in grams (±SD) of the ten NOD-Scid
mice-bearing patient derived xenografted tumors following three weeks of treatment with Irinotecan and
Bevacizumab. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in which
treatment was performed. On the right are indicated the different treatment arms. PBS: saline solution,
negative control. OXA (CPT11+Avastin): mice that failed Oxaliplatin and were then treated with
Irinotecan and Bevacizumab. doi:10.1371/journal.pone.0105710.g006
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Ependymoma Patient 2
Patient 2 was a five-month-old female with an aggressive brain tumor that was surgically
removed in April 2012. The tumor was diagnosed as an Anaplastic Ependymoma, WHO grade
III with low-grade mitosis-poor areas and high cellular tissue with mitosis and high MIB-1 rate.
A biopsy from the surgically removed tumor was placed in RPMI-1640 sterile media and
the tissue was dissociated in the laboratory into a single-cell suspension with the use of a
GentleMACS tissue dissociator (Miltenyi, Aubourn, CA) as done in the previous case. The
single-cell Ependymoma suspension was plated in RPMI-1640 in the presence of 5% irradiated,
heat inactivated, defined fetal bovine serum, streptomycin and penicillin and cells were cultured
as a monolayer for 15 days. Cells were immunophenotyped by flow cytometry using antibodies
against CD34, CD38, CD44, CD133, Nanog, and CXCR4. The Ependymoma cells were found
positive to Nanog (13%), CD133 (47.5%), CD44 (65.5%), and CXCR4 (89.7%) when compared
to an isotype control antibody. A double staining of CD34 and CD38 showed the presence of
4.6% of the cells CD34+/CD38+, and 47.3% CD34+/CD38- cells.
The chemotherapy sensitivity assay performed on the bulk of the Ependymoma cells and
on the CSLCs showed resistance to all of the tested chemotherapy drugs (Figure 13). Patient 2
received complex chemotherapy with six cycles of Vincristine, Carboplatin, Cyclophosphamide,
Etoposide, and Cisplatin in various combinations, however the tumor rapidly progressed and
proton beam therapy was recommended. The tumor did not respond to the various anticancer
drugs and radiation therapy and the patient expired after nine months.
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Figure 13. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to Chemotherapy of
Cancer Cells or CSLCs Using a WST-8 Assay on Ependymoma Case 2.
1×10³ bulk of tumor cells or CSLCs plated in five replicas into 96-well plates were challenged for a onehour pulse with a panel of anticancer drugs indicated by the oncologist. A WST-8 assay was performed
48 hours following chemotherapy treatments to assess cell viability. Data is plotted in bar graph as
responsive (0–40% cell viability), moderately responsive (40–70% cell viability), and non-responsive
(70–100% cell viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with respect to
negative untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the
bottom of the diagram. Statistical analysis of the significance of the results was performed with a one-way
ANOVA. Asterisks indicate p values of less than 0.05. doi:10.1371/journal.pone.0105710.g007
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DISCUSSION
Treatment for Ependymoma is often a combinatorial approach that includes surgery,
radiation therapy, and chemotherapy. Although chemotherapy has been used extensively in the
treatment management of Ependymomas, this therapeutic modality is often reserved for patients
with residual tumor after surgery and for children younger than three years of age in an attempt
to delay radiation therapy. Recently, the role of chemotherapy in the treatment of Ependymoma
has diminished because (1) chemotherapy fails to delay the need for radiation therapy for a
meaningful period of time; (2) tumors that progress during chemotherapy do not respond as well
to subsequent irradiation; and (3) the combination of chemotherapy and irradiation does not
improve overall survival (59,73).
It is not entirely clear why there is not an improved survival with chemotherapy (63),
therefore investigation and development of novel strategies and integrated therapies are required
to find more effective treatments for this type of tumor.
One of our patients was diagnosed with recurring undifferentiated intraduralextramedullary spinal Ependymoma, WHO grade III, with a distinctive sensitivity to
chemotherapy who has been followed up for five years following chemotherapy sensitivity
assay. The second patient was also diagnosed with recurring Ependymoma, WHO III but was
found not sensitive to any of the chemotherapies tested and rapidly progressed.
Resistance to chemotherapy severely compromises its effectiveness. The development of
resistance is a major problem for patients, researchers, and clinicians who rely on conventional
cytotoxic agents for the treatment of cancer.
Despite the fact that several treatments for Ependymoma are currently available, this
remains a poorly treated disease (74-78). Surgery plus postoperative radiotherapy represents the
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standard treatment for patients with grade III (Anaplastic) Ependymomas (78,79). Additionally,
surgery has been demonstrated to be associated with significant improvements in overall survival
time for patients with all stages of ependymal tumors (80-84); however, a total resection is not
always achieved. Overall prognosis is improved when the entire tumor can be removed and there
are no other neural axis metastases (85). Therefore, in cases in which the Ependymoma is
multifocal, metastatic, incompletely resected, or particularly aggressive, it is imperative to find
the most effective alternative treatment to surgery available.
Administration of ineffective anticancer therapy is associated with unnecessary toxicity
and development of resistant clones. Each time patients are treated, they have a chance of relapse
and their cancer may become more resistant to therapy. Presently used anticancer drugs have a
high rate of failure and cell culture chemotherapy testing is being used to identify which drugs
are more likely to be effective against a particular tumor type. Measuring the response of the
tumor cells to drug exposure is valuable in any situation in which there is a choice between two
or more treatments. In virtually all situations in cancer chemotherapy, the goal is cure or
palliation. This kind of testing can assist in individualizing cancer therapy by providing
information about the likely response of an individual patient’s tumor to proposed therapy. Many
attempts have been made over the years to develop an ex-vivo anti-cancer test that can provide
clinically relevant treatment information, but all the efforts have been directed toward the bulk of
tumor cells (86-92).
In the recent past, chemotherapy testing has been performed on cancer cells from patients
without prior separation and enrichment of the CSLCs from the bulk of tumor cells (9-12,87,9398).
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Knowing which chemotherapy agents the patient’s bulk of tumor cells, as well as the
CSLCs, are resistant to is very important. Then, these options can be eliminated, thereby
avoiding the toxicity of ineffective agents. Choosing the most effective agent can help patients to
avoid the physical, emotional, and financial costs of failed therapy and experience an increased
quality of life.
The chemotherapy sensitivity assay used in this study measures for the first time the
survival of CSLCs and bulk of tumor cells cultured from human cancer biopsies to
chemotherapeutic agents. The advantage of the chemotherapy sensitivity assay is to aid the
oncologists in selecting the most appropriate chemotherapy regimen on an individual basis
especially when a number of equivalent options are available. The chemotherapy sensitivity
assay allows various available chemotherapy drugs, which are part of standard of care to be
tested for efficacy against the cancer stem cells, as well as the bulk of tumors.
For Patient 1, affected by a recurring anaplastic Ependymoma, the chemotherapy
sensitivity assay determined on both bulk of tumor cells and CSLCs, that the most effective
treatments were either Irinotecan and Bevacizumab or Cisplatin. Interestingly, although the
entire regimen containing Irinotecan and Bevacizumab could not be completed, the patient
showed an initial regression of the disease and remained free from disease progression for 18
months, which corresponded to the longest disease progression free period in this patient.
Following up on the recurrence after the 18 month of progression free interval observed,
repeated testing was performed using the chemotherapy sensitivity assay on the combination of
several drugs and nutritional supplements, among which Benzyl isothiocyanate (BITC).
Numerous studies have indicated that Isothiocyanates (ITCs) induce robust anti-cancer effects
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(72,99,100). ITCs are derived naturally from glucosinolates, which are found at high
concentrations in vegetables from the Cruciferae family (71,72).
Cruciferous vegetables, which produce ITCs, include broccoli, Indian cress, cabbage,
Brussel sprouts, and watercress (101). ITCs are of interest as anticancer molecules because of
their ability to target many of the aberrant pathways associated with cancer development.
However, among the numerous ITCs identified, only a few of them appear to have anticarcinogenic properties (102).
Interestingly, BITC has been previously shown to increase the chemosensitivity of bulk
of tumor cells (71,72), but not of CSLCs. In this study it has been observed that BITC can
increase specifically the chemosensitivity of cells that are highly positive for CD133 (data not
shown), a marker used to identify CSLCs in tumors of the nervous system. Since the primary
Ependymoma cells of Patient 1 displayed a high percentage of cells positive to CD133, it was
advantageous to do further testing of the hypothesis that BITC could increase the patient’s
chemosensitivity.
Interestingly, as demonstrated here, for the first time, that the combination of Irinotecan
and BITC increased the chemosensitivity of the bulk of tumor cells and of the CSLCs cultured
from the Ependymoma of Patient 1. There was a clinically significant regression of the lesion in
the cervical area as well as regression of other lesions at the thoracic level following a combined
treatment with Irinotecan, Bevacizumab, and BITC.
Noteworthy and as expected, regression was observed of the NOD-Scid mice xenografts
treated with the most effective, the second most effective, and the most effective combinatorial
chemotherapy as determined by the in vitro chemotherapy sensitivity assay. In a model of patient
derived xenografts this confirms the clinical observation that Irinotecan and Bevacizumab are
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more effective anticancer drugs for this individual patient. Interestingly, the tumor xenografts in
the Scid mice injected with the least effective chemotherapy as determined by the in vitro
chemotherapy sensitivity assay grew faster than saline control injected mice. It is not known why
the tumor xenografts in mice injected with Oxaliplatin grew faster than saline control injected
mice, but speculated that because the patient was treated with Oxaliplatin prior to the
chemotherapy sensitivity assay biopsy, it had selected cellular clones that are resistant to it and
that manifest a growth advantage in its presence.
Furthermore, mice that did not show regression to Oxaliplatin treatment, which mimics
the clinical scenario of this particular patient, were rescued by switching them to a more effective
treatment (Irinotecan and Bevacizumab) as determined by the in vitro chemotherapy sensitivity
assay. As expected, in this rescue animal model the mice treated with a combination of
Irinotecan and Bevacizumab showed a regression of the patient derived xenografted tumors
compared to control mice injected with saline solution confirming once again the previously
observed clinical data.
Unfortunately, the second case of Ependymoma presented could not benefit from any
combined therapy that was proposed indicating that although affected by the same type of tumor
response to chemotherapy was different.
This is the first report on the clinical relevance of this novel chemosensitivity assay that
measures the sensitivity of bulk of tumor cells and CSLCs to chemotherapy, which has the
objective to decrease unnecessary toxicity while increasing the benefit of cytotoxic therapy for
patients affected by malignant tumors.
Although the chemotherapy sensitivity assay results on these two cases of Ependymoma
showed clinical relevance, a larger study with different histological tumor types is needed to
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determine the prognostic accuracy of this assay. This laboratory is currently conducting a brain
and spine malignant tumor phase-I clinical trial in which 33 patients have accrued in the past
three years to study the feasibility of this new assay in predicting the most effective
chemotherapy regimen to improve patients’ outcomes by assessing the vulnerability to
chemotherapy of the CSLCs.
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CHAPTER 3 CASE STUDY OF GLIOBLASTOMA
ABSTRACT
Among the different types of central nervous system (CNS) tumors, glioblastoma
multiforme (GBM) is the most aggressive and malignant primary brain tumor, exhibiting the
highest mortality rate among the glioma subtypes, with a median survival of 14 months. GBM is
persistently chemoresistant with substantial rates of reoccurrence. Most patients with GBM are
treated with surgery followed by chemo-radiation therapy either at the time of initial diagnosis or
at tumor recurrence.
This study was designed to investigate an in vitro chemotherapy sensitivity assay, which
measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy
agents for two Glioblastoma (GBM) patients. Patient 1 was a 56-year old male affected by a
GBM IDH-1 mutant. This patient was found 50% sensitive to the treatment of Temodar (TMZ)
on the bulk of the tumor, but resistant to TMZ when treating the CSC population. Six months
after initial therapy (surgery, TMZ and radiation) a recurrence was observed. Patient 2 was a 35year old male with GBM IDH-1 wild-type. This patient was also treated with surgery followed
by TMZ and radiation and at the six months follow up was found in remission. This event was
predicted by the chemotherapy sensitivity assay that indicated a response of both CSLC and Bulk
of tumor cells to TMZ.
The results of the in vitro assays were confirmed by the use of mice bearing patient
derived xenografts treated with the drugs screened by the chemotherapy sensitivity assay. The
animal data was found to be in accordance with the data from both the patients’ outcome and the
in vitro studies. This assay demonstrated again that patients with the same histological stage and
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grade of cancer may not always respond to the same standard-of-care clinical treatment,
suggesting that a chemotherapy sensitivity assay which measures the sensitivity of CSLCs as
well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more effective
and personalized anticancer treatments in the future.
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INTRODUCTION
Glioblastoma (GBM) or WHO grade IV malignant glioma is diagnosed in about 10,000
patients a year, making it the most common primary brain cancer in adults (46,52,103-105).
Standard treatment usually consists of surgery followed by chemo-radiotherapy allowing for an
average survival rate of only 14 months (3,52,103-108). The first line chemotherapeutic agent
used is an oral medication called Temozolomide (Temodar, TMZ); it is an alkylating agent,
disrupting DNA replication (3,6,52,104-107).
Though advancements have been made in the treatment of GBM most patients have
recurrence within a year (107). This poor prognosis has been associated with GMB
heterogeneity, and the CSLC that initiate and maintain this disease (3,46,52,104). Several studies
have identified biomarkers of anticancer drug resistance as well as tumor initiation
(3,6,46,52,104). The subpopulation of CD133 positive cells has been shown to contain tumor
initiator cells for GBM (3,46). This evidence supports the Cancer Stem Cell Hypothesis, and
indicates that targeting this population would lead to novel treatments that significantly improve
patient survival (46,52).
There is an indication that some factors of the patient that may influence the survival rate
and treatment resistance in patients include the status of the IDH1 gene and the methylation
status of the O6-methylguanine-DNA-methyltransferase gene (MGMT) (3,6,108). The IDH-1
gene encodes for cytosolic NADP+-dependent isocitrate dehydrogenase, which is involved in the
control of oxidative cellular damage. It has been found that patients that have a mutation in the
IDH-1 gene have better prognosis (108). The IDH-1 gene encodes for an enzyme located in the
cytoplasm and in peroxisomes that catalyzes the oxidative carboxylation of isocitrate to αketoglutarate, which allows the reduction of NADPH. The production of NADPH is essential for
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the regeneration of reduced glutathione, which functions as the main antioxidant in mammalian
cells and promotes resistance to apoptosis. IDH-1 therefore plays a prominent protective role
against oxidative damage induced by ROS via the regeneration of reduced glutathione (109).
In this context, mutation of IDH-1 appears paradoxical: on one hand, mutant IDH-1 cells
may be more sensitive to genetic instability caused by an oxidative environment, and thus IDH-1
mutations may contribute to tumor development, but on the other hand, mutant IDH-1 cells are
less protected against oxidative cellular damage (109).
This study investigated the chemosensitivity of Bulk of tumor cells and CSLC in two
primary cell lines generated from two patients who were newly diagnosed with GBM and never
treated before. GBM Patient 1 was found IDH-1 mutant and in GBM Patient 2, IDH-1 was found
to be wild-type (Wt).
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MATERIALS AND METHODS
Cell Culture and Reagents
All cell culture was performed using previously established methods (50). All clinical
grade chemotherapeutic agents were acquired as a gift from Edwards Comprehensive Cancer
Center.

Patients
Case 1 is a 56-year-old male patient diagnosed with an IDH-1 mutant GBM. Case 2 is a
35-year-old male with a IDH-1 wild type GBM. Chemotherapy sensitivity assay was performed
after obtaining patient’s written informed consent in accordance with the ethical standards of the
Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association.
Any information, including illustrations, has been anonymized. The Marshall University
Institutional Review Board (IRB) has approved this research under the protocol #326290. Ethics
committees/ IRB at Marshall University approved this consent procedure.

Three-Dimensional Bioreactor CSCs Culture
A hydrodynamic focusing bioreactor (HFB) (Celdyne, Houston TX) was used as
previously described to selectively proliferate the CD133 (+) cancer stem-like cells (45).

Cell Sorting
Up to 10 million cells were sorted for CD133+ cells by a magnetic-activated cell sorting
(MACS) system as described before (50).
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Flow Cytometry Studies
Cells were analyzed by the antigenic criteria using anti-CD34 (Milteny Biotech, Auburn,
CA), -CD38 (Milteny Biotech, Auburn, CA), -CD44 (BD Bioscience, Sparks, MD), -CD133/2
(prominin1) (Milteny Biotech, Auburn, CA), -CXCR4 (BD Bioscience, Sparks, MD), -Oct3/4
(BD Bioscience, Sparks, MD), and –Nanog (BD Bioscience, Sparks, MD). All methods were
performed as previously described (50).

Chemotherapy Sensitivity Assay
Sensitivity to chemotherapy was assessed using the viability assay MTT on 10,000 cells
plated in four replicas into 96-well plates. Briefly, equal numbers of bulk tumor cells grown in a
monolayer and CSLCs grown in the bioreactor, were counted and seeded separately in 96-well
dishes and incubated at 37°C for 24 hours. The cells were then challenged with a one-hour pulse
of a panel of individual anticancer drugs as chosen by the oncologist to mimic the average
clinical chemotherapy infusion schedule.
An MTT assay was performed 24 hours following chemotherapy treatment to assess cell
viability. A dose response chart was developed in which samples were scored as responsive
(100–60% cell death), intermediate (60–30% cell death), and non-responsive (0–30% cell death).

Animal Study
All animal studies were conducted following approval from the Marshall University
IACUC, protocol #373017. The effects of chemotherapies screened in vitro by the chemotherapy
sensitivity assay were tested on human tumor biopsies that were xenografted in the flank of a
NOD-Scid mouse model. This was performed using a previously established method (50).
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Animals were euthanized following the current guidelines established by the latest Report
of the AVMA Panel on Euthanasia using CO2 inhalation and asphyxiation followed by cervical
dislocation.

Statistical Analysis
Statistical analysis was performed as previously established (50). P-values of less than
0.05 were considered statistically significant.

66

RESULTS
Patient 1
The patient is a 56-year-old male who had a craniotomy on April 18th 2012. The
pathology report came back as Glioblastoma IDH-1 mutant. Appropriate informed consent was
signed and at the time of the debulking surgery, a sterile biopsy was taken to assess the
sensitivity of the tumor cells (bulk of tumor and CSLCs) toward standard-of-care chemotherapy
drugs using a chemotherapy sensitivity assay. The biopsy was placed in collection/transport
media and tissue was dissociated in the laboratory into a single-cell suspension with the use of a
GentleMACS tissue dissociator (Miltenyi, Aubourn, CA). The single-cell GBM suspension was
plated as previously reported (50) and cells were cultured as a monolayer for 15 days. Cells were
immunophenotyped by flow cytometer using antibodies against CD133, CD34, CD38, CD44,
CD24, CXCR4, OCT3/4, and Nanog (Figure 14).
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A

E

Negative

CD133 PE

B

F

C

Isotype PE

Isotype Fitc & APC

G

Isotype Fitc

CD34 APC & CD38 FITC

D

Isotype APC

H

CXCR4 APC

G

I

CD24 PE

J

CD44 APC

K

OCT4 APC

L

Nanog Fitc

Figure 14. Flow Cytometer Data for GBM Patient 1.
FL1-A is the filter used to measure Fitc, FL2-A is the filter used to measure PE, FL4- A is used to
measure APC. A) Negative control showing FSC and SSC on cells not labeled with any antibody. B)
Isotype control for PE. C) Isotype control for Fitc. D) Isotype control for APC. E) CD133/2-PE labeled
cells. F) Isotype control for Fitc vs APC. G) CD38-Fitc Antibody vs CD34-APC. Upper left quadrate is
CD34+/CD38-, upper right quadrant is CD34+/CD38+, lower left quadrant is CD34-/CD38-, and lower
right quadrant is CD34-/CD38+. H) CXCR4-APC labeled cells. I) CD24-PE labeled cells. J) CD44-APC
labeled cells. K) OCT 3/4-APC labeled cells. L) Nanog-Fitc labeled cells.
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Percent

CD133
9.8

CD44
72.4

CD24
29.7

CXCR4
75.0

OCT3/4
13.6

Nanog
0.2

CD34+/CD3863.5

Table 3. Flow Cytometer Data on GBM Patient 1.
Shows the percent of cells tested that are positive for each biomarker compared to the Isotype controls.

The GBM cells were found positive to CD133 (9.8%), CD44 (72.4%), CD 24 (29.7%),
CXCR4 (75.0%), OCT3/4 (13.6%), and Nanog (0.2%) when compared to an isotype control
antibody (Table 3). A double staining of CD34 and CD38 showed the presence of 1.6% of the
cells CD34+/CD38+, and 63.5% CD34+/CD38- cells (Table 3). To expand the CSLC population
of CD133+ cells from the GBM primary culture, the cells were cultured as previously described
(50). 1x10 GBM cells were cultured in the HFB to isolate the CSLCs for chemotherapy
sensitivity assay. When placed directly in non-attaching dish they maintained a cluster assembly
(Figure 15A) and would repopulate the morphologically heterogeneous GBM culture after ten
days in a regular tissue culture dish (Figure 15B).

Figure 15. GBM Patient 1 Cells Cultured in Low Attachment Dish and Tissue Culture Treated Dish after
being isolated for CD133 in HFB for seven days.
A) GBM Patient 1 cells cultured in a low attachment dish after being isolated for CD133 using the HFB.
Picture taken after three days in culture. B) GBM Patient 1 cells cultured in a tissue culture treated dish
after isolated for CD133 using the HFB. Picture taken after three days in culture.
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To perform the chemotherapy sensitivity assay, a comparable number (1x10⁵) of bulk of
tumor cells grown, as a 2D monolayer, or isolated for CD133 using the HFB (50), were separately
plated into 96 wells plates (n-4 replicas) and were treated for an hour with a series of anticancer
drugs at a range of concentrations including the clinically relevant dosage (Table 4).
Chemotherapy sensitivity assay was performed using a panel of drugs comprising of Temodar,
Carboplatin, Cisplatin, Etoposide, Methotrexate, Arabinoside-C, Oxaliplatin, Irinotecan, and
Bevacizumab. Sensitivity to chemotherapy was assessed at 24 hours by MTT viability assay.
Results were categorized as follows based on the percentage of non-viable cells: responsive
(100–60% cell kill), intermediate (30–60% cell kill), and non-responsive (0–30% cell kill). The
MTT assay was conducted three separate times with n-4 well replicas/drug/dose each time
(Figure 16).

Clinical
Dose
Calculated
in vitro
dose

TMZ

VCR

CPL

CDDP

VP16

MTX

Ara-C

OXA

CPT-11

Avastin

150
mg/m²

2
mg/m²

400
mg/m²

80
mg/m²

200
mg/m²

500
mg/m²

2000
mg/m²

80
mg/m²

125
mg/m²

10
mg/kg

1.23mM

3.5µM

1.72mM

0.43mM

0.54mM

1.36mM

13.16mM

0.32mM

0.32mM

4.4µM

Table 4. Clinical Dose and Calculated in vitro Doses of Chemotherapy for GBM Patients.

Chemotherapy sensitivity assay showed that the bulk of tumor of Patient 1 cells grown in
monolayer and were intermediately responsive to clinically relevant doses of Temodar (TMZ),
Irinotecan (CPT-11) + Bevacizumab (Avastin) combination, Cisplatin (CDDP), Irinotecan (CPT11), Methotrexate (MTX), and Oxaliplatin (OXA). Interestingly, the CSLCs were only
intermediately responsive to a combination of Irinotecan (CPT-11) and Bevacizumab (Avastin)
(p< 0.05), and were not responsive to any other treatment including Temodar (TMZ) (Figure 16).
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% Cell Death Compared to the Control
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*
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*

*
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Figure 16. Diagram of Chemotherapy Sensitivity Assay to Assess the Response to GBM Patient 1 cells
and CSLCs Using MTT Assay.
1x10³ bulk of tumor cells or CSLCs plated in four replicas into 96-well plates and allowed overnight to
attach. Then cells were challenged with a one-hour pulse of varying chemotherapeutic agents. A MTT
assay was performed 24 hours following chemotherapy treatments to assess cell viability. Data is plotted
in bar graph as responsive (100–60% cell death), intermediately responsive (60–30% cell death), and nonresponsive (0–30% cell death). Light grey bars represent sensitivity of CSLCs to chemotherapy with
respect to negative untreated control cells. The black bars represent sensitivity of bulk of tumor cells to
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the
bottom of the diagram. Statistical analysis of the significance of the results was performed with a one-way
ANOVA. Single asterisk indicate p values of less than 0.05. Double asterisks indicate p values of less
than 0.01.
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This patient was treated with surgery followed by standard-of-care first-line therapy of
Temodar and radiation. At the six months follow-up this patient showed an initial response
demonstrated by the diminished size of the tumor at the MRI, but was found to have a tumor
relapse at the 12 months follow-up (Figure 17 A, B, & C). Unfortunately, as shown in the
follow-up MRI scan at 18 months, the tumor had continued to progress causing the patient to
expire (Figure 17 A & D).
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Figure 17. MRI Images from GBM Patient 1.
A. Preoperative MRI of the brain with left frontal lobe GBM crossing the midline into the left frontal lobe
& invading the corpus callosum with large amount of associated edema & hydrocephalus. B. Postoperative MRI six months post resection & radiation showing regression of the disease. C. 12 months
post therapy MRI showing progression of residual disease. D. 18 months post therapy MRI showing
progression of the disease back to bi-frontal mass with increased invasion of corpus callosum and mass
affecting on the ventricular system with return of hydrocephalus.

Table 5. GBM Patient 1 Predicted Response and Disease Outcome.
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Patient 2
Patient 2 is a 35-year-old male who had a craniotomy on June 11th 2012. Pathology
report came back as Glioblastoma IDH-1 wild type. Appropriate informed consent was signed
and at the time of the debulking surgery, a sterile biopsy was taken to assess the sensitivity of the
tumor cells (bulk of tumor and CSLCs) toward standard-of-care chemotherapy drugs using our
chemotherapy sensitivity assay. The biopsy was placed in collection/transport media and tissue
was dissociated in the laboratory into a single-cell suspension with the use of a GentleMACS
tissue disassociator (Miltenyi, Aubourn, CA). The single-cell GBM suspension was plated as
previously reported (49) and cells were cultured as a monolayer for 15 days. Cells were
immunophenotyped by flow cytometry using antibodies against CD133, CD34, CD38, CD44,
CD24, CXCR4, OCT3/4, and Nanog (Figure 18).
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A

Negative

B

Isotype PE

E

CD133 PE

F

Isotype APC & Fitc

G

CD34 APC & CD38 Fitc

H

CD44 APC

I

CD24 PE

J

CXCR4 APC

K

OCT4 APC

L

Nanog Fitc

C

Isotype Fitc

D

Isotype APC

Figure 18. Flow Cytometer Data for GBM Patient 2.
FL1-A is the filter used to measure Fitc, FL2-A is the filter used to measure PE, FL4- A is used to
measure APC. A) Negative control showing FSC and SSC on cells not labeled with any antibody. B)
Isotype control for PE. C) Isotype control for Fitc. D) Isotype control for APC. E) CD133/2-PE labeled
cells. F) Isotype control for Fitc vs APC. G) CD38-Fitc Antibody vs CD34-APC. Upper left quadrate is
CD34+/CD38-, upper right quadrant is CD34+/CD38+, lower left quadrant is CD34-/CD38-, and lower
right quadrant is CD34-/CD38+. H) CD44-APC labeled cells. I) CD24-PE labeled cells. J) CXCR4-APC
labeled cells. K) OCT 3/4-APC labeled cells. L) Nanog-Fitc labeled cells.
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Percent

CD133
12.3

CD44
11.9

CD24
16.6

CXCR4
43.6

OCT3/4
25.1

Nanog
4.9

CD34+/CD3813.1

Table 6. Flow Cytometer Data on GBM Patient 2.
Shows the percent of cells tested that are positive for each biomarker compared to the Isotype controls.

The GBM cells were found positive to CD133 (12.3%), CD44 (11.9%), CD 24 (16.6%),
CXCR4 (43.6%), OCT3/4 (25.1%), and Nanog (4.9%) when compared to an isotype control
antibody (Table 6). A double staining of CD34 and CD38 showed the presence of 1.6% of the
cells CD34+/CD38+, and 13.1% CD34+/CD38- cells (Table 6). To expand the CSLC population
of CD133+ cells from the GBM primary culture, the cells were cultured as previously described
(50). The GBM cells cultured and isolated for CD133 using the HFB for chemotherapy
sensitivity assay. When placed directly in non-attaching dish they maintained a cluster assembly
(Figure 19A) and would repopulate the heterogeneous GBM culture after ten days in a regular
tissue culture dish (Figure 19B).

Figure 19. GBM Patient 2 Cells Cultured in Low Attachment Dish and Tissue Culture Treated Dish after
being isolated for CD133 using the HFB.
A) GBM Patient 2 cells cultured in a low attachment dish after being isolated for CD133 using the HFB.
Picture taken after three days in culture. B) GBM Patient 2 cells cultured in a tissue culture treated dish
after being isolated for CD133 using the HFB. Picture taken after three days in culture.
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To perform the chemotherapy sensitivity assay 1x10⁵cells of either bulk of tumor cells
grown as a 2D monolayer or isolated for CD133 using the HFB (50) were separately plated into
96 wells plates (n-4 replicas) and were treated for an hour with a series of anticancer drugs at a
range of concentrations including the clinically relevant dosage as done for GBM Patient 1
(Table 4). Again, chemotherapy sensitivity assay was performed using a panel of drugs
comprising of Temodar, Carboplatin, Cisplatin, Etoposide, Methotrexate, Arabinoside-C,
Oxaliplatin, Irinotecan, and Bevacizumab. Sensitivity to chemotherapy was assessed at 24 hours
by MTT viability assay. Results were categorized as follows based on the percentage of nonviable cells: responsive (100–60% cell kill), intermediate (30–60% cell kill), and non-responsive
(0–30% cell kill). The MTT assay was conducted three separate times with n-4 well
replicas/drug/dose each time (Figure 20).
This patient was treated with surgery followed by standard-of-care first line
chemotherapy with Temodar and radiation therapy. Notably, at the six month post treatment
follow-up, the patient showed a positive response with tumor regression as demonstrated by an
MRI scan (Figure 21 A, B, & C). A follow-up MRI scan at 18 months showed no evidence of
tumor recurrence or progression at the operative bed or distantly (Figure 21 D).
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Figure 20. Diagram of Chemotherapy Sensitivity Assay to Assess the Response to GBM Patient 2 cells
and CSLCs Using MTT Assay.
1x10³ bulk of tumor cells or CSLCs plated in four replicas into 96-well plates and allowed overnight to
attach. Then cells were challenged with a one-hour pulse of varying chemotherapeutic agents. A MTT
assay was performed 24 hours following chemotherapy treatments to assess cell viability. Data is plotted
in bar graph as responsive (100–60% cell death), intermediately responsive (60–30% cell death), and nonresponsive (0–30% cell death). Light grey bars represent sensitivity of CSLCs to chemotherapy with
respect to negative untreated control cells. The black bars represent sensitivity of bulk of tumor cells to
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the
bottom of the diagram. Statistical analysis of the significance of the results was performed with a 1-way
ANOVA. Single asterisks indicate p values of less than 0.05. Double asterisks indicate p values of less
than 0.01.
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Figure 21. MRI Images from GBM Patient 2.
A. Pre-operative MRI of the brain showing a rim-enhancing GBM in the left cerebrum with edema
causing mass effect on the ventricles and ballooning of the left temporal horn & mass effect on the basal
cistern. B. Post-surgical resection MRI shows linear non-nodular enhancement likely related to surgery.
C. Six months post therapy MRI without evidence of tumor recurrence. D. 18 months post therapy
without evidence of tumor recurrence or progression at the operative bed or distantly.

Table 7. GBM Patient 2 Predicted Response and Disease Outcome.
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Animal Study
The efficacy of chemotherapies screened in vitro by the chemotherapy sensitivity assay
was tested on the GBM cells of Patient 1 and Patient 2 that were xenografted in a NOD-Scid
mouse model (Figure 22 & 23). Ten athymic NOD-Scid mice were injected in the flank with
1x10 GBM cells mixed to 100 µL of matrigel (BD Biosciences, San Jose, CA) and tumors were
grown for ten weeks or until 100 mm³. Randomized mice were treated by weekly intraperitoneal
(i.p.) injections of the different treatments for four weeks and were observed for four more
weeks. Group #1 serving as a control received i.p. sterile saline injections. Groups #2–6 were the
experimental groups, which received i.p. injections of the least effective chemotherapy, or the
most effective, the second most effective, and the most effective combinatorial chemotherapy, as
determined by the in vitro chemotherapy sensitivity assay.
The tumor xenografts in the Scid mice injected with the least effective chemotherapy as
determined by the in vitro chemotherapy sensitivity assay grew faster than any other treatment
other than the saline control injected mice (Figure 22 Top 23 Top).
Interestingly, tumor regression was initially seen in Scid mice injected with cells from
GBM Patient 1 treated TMZ, but after treatment was stopped, at week six, tumor began to grow
again (Figure 22 Top). This was confirmed with clinical patient data (Figure 17) that showed
after treatment of TMZ and radiation the patient relapsed. The best response by cells from GBM
Patient 1 was to combinatorial chemotherapy of CPT-11 + Avastin as determined by the in vitro
chemotherapy sensitivity assay. Mice weights were measured weekly (Figure 22 Bottom).
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Figure 22. Mean Tumor Volume and Mean Tumor Weight of GBM Patient 1 Derived Xenografts Treated
with i.p. Injection of Anticancer Drugs.
Top) Line diagram of the mean volumes in mm³ (±SD) from week 2–8 of ten GBM Patient 1 derived
xenografted tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs.
The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was
performed. On the right are indicated the different treatment arms. PBS: saline solution, negative control.
Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); CPT-11 (Irinotecan) +
Avastin (Bevacizumab). Bottom) Line diagram of the mean weight in grams (±SD) of ten NOD-Scid
mice-bearing patient derived xenografted tumors following four weeks of treatment with various
anticancer drugs. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in
which treatment was performed. On the right are indicated the different treatment arms. PBS: saline
solution, negative control. Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab);
CPT-11 (Irinotecan) + Avastin (Bevacizumab).
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Tumor regression was reported in Scid mice injected with GBM cells from Patient 2,
which were treated with the most effective chemotherapy (TMZ) that was confirmed to be the
most effective treatment in the in vitro chemosensitivity test (Figure 23 Top). This was
confirmed by the clinical patient data (Figure 21) that showed after treatment of TMZ and
radiation the patient was in remission. The second best response of GBM Patient 2 was to
combinatorial chemotherapy of CPT-11 + Avastin as predicted by the in vitro chemotherapy
sensitivity assay and as determined by the xenograft treatment. Mice weights were measured
weekly (Figure 23 Bottom).
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Figure 23. Mean Tumor Volume and Mean Tumor Weight of GBM Patient 2 Derived Xenografts Treated
with i.p. Injection of Anticancer Drugs.
Top) Line diagram of the mean volumes in mm³ (±SD) from week 2–8 of ten GBM Patient 2 derived
xenografted tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs.
The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was
performed. On the right are indicated the different treatment arms. PBS: saline solution, negative control.
Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); CPT-11 (Irinotecan) +
Avastin (Bevacizumab). Bottom) Line diagram of the mean weight in grams (±SD) of ten NOD-Scid
mice-bearing patient derived xenografted tumors following four weeks of treatment with various
anticancer drugs. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in
which treatment was performed. On the right are indicated the different treatment arms. PBS: saline
solution, negative control. Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab);
CPT-11 (Irinotecan) + Avastin (Bevacizumab).
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DISCUSSION
Treatment for Glioblastoma (GBM) is often a combinatorial approach that includes
surgery, radiation therapy, and chemotherapy. Temozolomide (TMZ) is the primary
chemotherapeutic agent used in the treatment of GBM but is often non-curative and patients
frequently experience tumor relapse due to chemoresistance.

As shown in this study of two GBM cases the different responses to chemotherapy
determined by the chemosensitivity assay on the CSLCs resulted in a distinct and opposite
outcome for the patient.
To advance our ability to more thoroughly understand the CSLC driving force within
heterogeneous tumors such as GBMs, a procedure that can successfully enrich the CSLC
population from tumor biopsy specimens was developed. These enriched CSLCs are then used to
assess their intrinsic resistance or sensitivity to chemotherapy vs. the resistance of primary
cultures derived from the total heterogeneous tumor. This method successfully facilitated the
enrichment of CD133+ CSLCs from fresh GBM biopsy tissues allowing the selective evaluation
of chemotherapy response of the CSLC population compared to the response of the parenteral
heterogeneous tumor cell population. Results using this procedure showed that GBM tumors do
contain populations of CSLCs that can be selectively enriched, and that the chemoresistance or
sensitivity status of CSLCs to TMZ predicted the patients’ treatment outcome in GBM patients
receiving the standard-of-care Temozolomide (TMZ) regimen.
GBM Patient 1 was diagnosed with a GBM IDH-1 mutant, which should have
experienced a better outcome following treatment with TMZ. However, following standard
chemoradiation treatment a recurrence was observed within six months. GBM patient 2, who
was diagnosed with a GMB, but IDH-1 wild type, should have had worse prognosis following
standard chemoradiation treatment. Instead patient 2 showed a positive response with tumor
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regression as demonstrated by MRI scans indicating that genetic analysis, of a single marker, to
predict tumor response may not be an accurate method of patient stratification.
This study accurately predicted that Patient 1 would relapse because the CSLCs would
not be affected by the TMZ treatment, thereby causing the CSLCs to reinitiate the tumor. In
contrast, Patient 2 was predicted to respond well to the treatment received by the chemotherapy
sensitivity assay. Figure 24 shows the responses of GBM Patient 1 and 2 to TMZ using the
chemotherapy sensitivity assay.
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Figure 24. Diagram of GBM Patient 1 and Patient 2 Response to TMZ using the Chemotherapy
Sensitivity Assay on both the Bulk of the tumor and the CSLCs.

This outcome was also challenged using NOD-Scid mice xenografts treated with the most
effective, the second most effective, and the most effective combinatorial chemotherapy as
determined by the in vitro chemotherapy sensitivity assay. As expected, results from tumor
xenografts generated by injecting enriched GBM CSLCs from the two patients in the flank of
NOD-Scid mice, followed by treatment with select chemotherapies, were also found to be in
agreement with the clinical outcomes for the patients’ response to TMZ at follow-up. Regression
was observed at first in tumor xenografts from Patient 1 cells treated with TMZ; however,
following cessation of the TMZ treatment relapse was observed (Figure 22). Interestingly,
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xenografts from Patient 2 treated with TMZ, responded well to the treatment and a regression of
the tumors was observed (Figure 23).
This data shows the importance of determining the sensitivity of CSLCs to chemotherapy
and their role in predicting patient tumor response following chemotherapy. This data further
supports our belief that long-term tumor response in GBM is in fact more dependent on the
intrinsic sensitivity or resistance of the CSLC population than the general tumor cell population
and needs to be closely studied to determine how this population can be targeted for therapy.
This method will provide critical information about an individual patient’s possibility to achieve
a complete tumor response status before implementing the patient’s treatment plan. Although the
chemotherapy sensitivity assay results of these two cases of GBM showed to be clinically
relevant, this laboratory is currently conducting a larger study on a series of GBMs to determine
the prognostic accuracy of this assay.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
Chapter 1 reviewed the current literature on CNS cancer treatments, cancer stem cell
theory, and standard-of-care anticancer drugs. In this chapter the potential for chemotherapy
sensitivity assay on cancer stem-like cells to establish personalized patient therapy was
highlighted. The method of how this assay is performed and its validation is also outlined in this
chapter.
Chapter 2 discussed the relevance and outcome of two patients affected by Ependymoma.
The ependymoma of Patient 1 was found sensitive to a combination of Irinotecan + Avastin, but
resistant to Oxaliplatin. This data was confirmed by an animal study in which mice treated with
Oxaliplatin and failing therapy could be rescued with a combination of Irinotecan + Avastin.
This study also showed that an adjuvant supplementation of BITC extracted from broccoli
sensitized CSLCs to chemotherapy and increased its efficacy both in vitro and in vivo.
Unfortunately, the ependymoma of patient 2 was found not responding to the chemotherapies
used and was also resistant to the same anticancer drugs when tested in the in vitro
chemosensitivity assay.
In Chapter 3, the chemotherapy sensitivity assay was investigated in two glioblastoma
cases. The CSLCs of GBM Patient 1 were found resistant to TMZ by the chemotherapy
sensitivity assay. Following a regimen of chemoradiation with TMZ this patient relapsed after a
year. The clinical outcome of patient 1 was found in accordance with both the in vivo and in vitro
studies performed in the laboratory. GBM Patient 2 was also treated with chemoradiation with
TMZ, but interestingly this patient showed a completely different clinical outcome being free
from progression for 18 months. In patient 2, the chemotherapy sensitivity assay accurately
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predicted that both bulk of the tumor cells and CSLCs would respond to TMZ, which was also
confirmed by a study conducted using mice xenografts.
The chemotherapy sensitivity assay has shown great promise in these four cases. This
assay demonstrated that the CSLC population must be assayed to better predict patient outcomes
because of the known resistance of CSLCs to anticancer drugs. By combining the information
gathered for both Bulk and CSLC population, new treatment modalities could be established that
could lead to increased survival rates.
In addition, the clinical study presented above suggests that future studies of natural
compounds such as BITC and others should be performed to further increase our understanding
of the potential of botanical extracts and compounds as adjuvant to chemotherapy.
One of the shortcomings of the present study is that O 6-methylguanine DNA
methyltransferase (MGMT) status was not investigated on the samples. MGMT gene encodes for
a protein that is involved in DNA repair by removing the alkyl groups (108). This is problematic
for proscribed chemotherapeutic drugs, like TMZ, that are alkylating agents that place alkyl
groups on the DNA so that replication cannot occur (108). MGMT activity is regulated by
epigenetic factors that methylate the promoter region of the gene to reduce the amount of
MGMT in a GBM cell (108). MGMT gene methylation has been shown to be associated with
improved outcome in GBM and may be a predictive marker of sensitivity to alkylating agents.
While MGMT status of these tissues has not been examined, it is an experiment to consider for
the future.
Another shortcoming of the present studies is the lack of large clinical data; however, the
clinical data from a series of twenty-five GBMs is currently being evaluated. In conclusion, this
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present body of work supports the knowledge that chemotherapy sensitivity assays on CSLCs are
a promising tool to more accurately predict patient outcome following anticancer treatment. This
assay has the potential to be standardized and used in clinical settings, being novel in its
approach to analyze the sensitivity/resistance of CSLCs to anticancer drugs and hopefully
sparing future patients from being treated with ineffective drugs.
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